AFC Agro Biotech Ltd.
DDSE:AFCAGRO4.90
BDT
0.00
(0.00%)
ISIN
BD0489AFCAB3
Return %
Stock
S&P 500
1Y
-23.44
14.39
3Y
-79.15
81.42
5Y
-82.87
68.62
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Mohammed Afzal
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Dhaka Bangladesh
- IPO Date
- Oct 27, 2013
- Similar Companies
- Business
- AFC Agro Biotech Ltd. is a Bangladesh-based biotechnology and specialty biochemical company that manufactures and distributes agricultural-based bio-pharmaceuticals, active pharmaceutical ingredient (API) intermediates, and industrial chemical products. Incorporated in August 2010 and headquartered in Dhaka, Bangladesh, the company operates a multi-purpose manufacturing plant situated in Batiaghata, Khulna, and functions as an associated backward-linkage supplier to Active Fine Chemicals Limited. The company utilizes agricultural raw materials, including molasses, glucose, potato starch, and corn starch, across fermentation and biochemical synthesis processes. AFC Agro Biotech Ltd. organizes its core product portfolio into several distinct categories: antibiotics, including erythromycin used for therapeutic treatment of respiratory infections and penicillin-allergic patients; amino acids and nutritional proteins, including L-lysine and methionine for animal nutrition and human pharmaceutical formulations; biological enzymes and agricultural additives; organic chemical compounds, including acetic acid and monosodium glutamate; inorganic chemical compounds, including sodium carbonate, magnesium carbonate, and calcium hydrogen orthophosphate; and laboratory-grade reagents and raw inputs for active pharmaceutical ingredient production. In recent developments, AFC Agro Biotech entered into a strategic collaboration agreement with South Korea-based Bioneer Corporation to manufacture and distribute molecular diagnostic kits, real-time PCR instruments, and related diagnostic consumables for healthcare markets in Bangladesh and regional ASEAN territories. Furthermore, the company has undergone recent operational restructuring and regulatory scrutiny following the suspension of manufacturing activities at its Khulna production facility, verified by Dhaka Stock Exchange inspection teams, leading to its reclassification into the Z category on the Dhaka Stock Exchange amid non-compliance with periodic corporate disclosure requirements.